AIM ImmunoTech Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AIM American 2834 https://aimimmuno.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc

AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise - Mar 30th, 2023 12:45 pm
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - Mar 27th, 2023 1:05 pm
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease - Mar 16th, 2023 12:45 pm
AIMIA DECLARES PREFERRED SHARE DIVIDENDS - Mar 16th, 2023 11:00 am
AIMIA REPORTS FOURTH QUARTER 2022 RESULTS - Mar 16th, 2023 11:00 am
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease - Mar 8th, 2023 1:45 pm
AIM ImmunoTech Issues Letter to Stockholders - Mar 6th, 2023 1:45 pm
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients - Feb 28th, 2023 1:45 pm
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?” - Feb 17th, 2023 1:55 pm
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center - Jan 17th, 2023 1:45 pm
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th - Jan 11th, 2023 6:00 pm
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention - Jan 9th, 2023 1:05 pm
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’ - Jan 5th, 2023 1:45 pm
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer - Dec 12th, 2022 2:00 pm
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects - Dec 8th, 2022 1:05 pm
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022 - Dec 2nd, 2022 3:45 pm
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 15th, 2022 12:00 pm
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer - Nov 14th, 2022 12:00 pm
AIM ImmunoTech Announces Corporate Governance Enhancements - Nov 9th, 2022 2:00 pm
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting - Nov 3rd, 2022 4:34 pm